Cytox launches breakthrough genetic biomarker research assay for Alzheimer’s risk assessment. Simple blood-based test will help reduce screening failu ...

Affymetrix and Cytox have agreed to collaborate on developing and commercializing a blood-based genetic assay for research in diagnosis and prognosis of Alzheimer’s disease (AD) and mild ...

Cytox Ltd, (Cytox) a leading developer of assays for risk assessment and prediction of dementia, announced the start of two landmark exploratory clinical trials designed to evaluate a new blood ...

Cytox and Affymetrix form strategic partnership to develop and commercialize blood-based genetic assay for Alzheimer’s disease.

Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, has confirmed its participation in the pioneering French INSIGHT study of Alzheimer’s disease (AD ...

U.K. diagnostics developer Cytox raised nearly $2.5 million in new funding to help expand work on the development of a viable Alzheimer's biomarker.

The U.K.’s Cytox has launched the research use of its variaTECT genetic biomarker test for assessing the risk of Alzheimer’s disease.

Cell viability assay The C2C12 cells viability in the nanofibres was investigated using the Trypan blue assay and the EZ-Cytox Cell viability assay kit (water-soluble tetrazolium salt method).

Affymetrix Inc (AFFX) recently announced that it has entered into a strategic partnership with Cytox, a developer of assays for risk assessment and prediction of dementia.

Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, has announced the launch of its research use varia TECT™ genetic biomarker test for assessing ...

Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, and Affymetrix (Nasdaq:AFFX), a leading provider of translational research and diagnostic solutions ...